AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

Thymalin research guide

Historical thymic preparation name; current composition requires verification

An identity-first guide to Thymalin as a historical thymic preparation, explaining why a name and total mass do not define one peptide or prove equivalence.

AUS Peptide Supply editorial team
thymaline

01 · Identity

What the name identifies

Historical primary reports describe Thymalin or thymaline as a thymic preparation or polypeptide factor, including material obtained from calf thymus. Those descriptions do not establish whether a modern product is an extract, an isolated peptide or a defined mixture. Current composition must be documented independently.

02 · Evidence position

What the literature can support

The selected historical abstracts establish preparation terminology and report clinical or analytical observations, but they do not provide enough composition and trial-design detail to validate a modern catalogue material. Thymosin Alpha-1 is a separately defined peptide and should not be treated as a synonym.

03 · Study-level map

Evidence and its limits

Analytical identity

How was the historical preparation described?

A 1984 report in 36 patients described thymaline obtained from calf thymus. This identifies the historical preparation context, not the source of current stock.

Limit: The indexed abstract does not provide a complete component profile or establish equivalence to a later product bearing the same name.

Analytical identity

What kind of analytical work was reported?

A 1987 study developed an indirect enzyme immunoassay for thymalin, described as a polypeptide thymus factor.

Limit: An immunoassay response is not a complete sequence-level identification or quantitative profile of every component in a preparation.

Analytical identity

Why distinguish Thymosin Alpha-1?

The original Thymosin Alpha-1 sequence study identified a particular 28-residue peptide. That level of molecular definition cannot be assigned to an unspecified preparation by name alone.

Limit: No claim is made that a Thymalin-labelled vial contains that peptide or any fixed proportion of it.

04 · Analytical context

Questions a batch record should answer

  1. 01Does the supplier identify the material as an extract, defined mixture or isolated compound?
  2. 02Are component identities, proportions and manufacturing origin documented for this exact material?
  3. 03Can the analytical method distinguish the intended preparation from similarly named thymic products?

05 · Boundary conditions

What this record does not establish

  • The supplied composition is not established by the Thymalin name or a 10mg label.
  • Historical calf-thymus origin must not be asserted for current stock without evidence.
  • No verified APS CoA or component-resolved composition record is available for the associated product at publication.

Sources checked

  1. 1.
    Use of a thymus polypeptide preparation to diagnose and correct immune deficiency states in multiple sclerosis

    Golovkin et al. — Zhurnal Nevropatologii i Psikhiatrii / PubMed · 1984 · Primary study

  2. 2.
    Immunoenzyme method of determining thymus polypeptide factor

    Moskvicheva et al. — Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii / PubMed · 1987 · Primary study

  3. 3.
    Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide

    Goldstein et al. — Proceedings of the National Academy of Sciences / PubMed · 1977 · Primary study

Continue through the topic